title: Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
abstract: L-DOPA treatment of Parkinson's disease induces a high incidence of motor complications, notably dyskinesia. Longer acting dopamine agonists, e.g. ropinirole, are thought to produce more continuous dopaminergic stimulation and less severe dyskinesia. However, standard oral administration of dopamine agonists does not result in constant plasma drug levels, therefore, more continuous drug delivery may result in both prolonged reversal of motor deficits and reduced levels of dyskinesia. Therefore, we compared the effects of repeated oral administration of ropinirole to constant subcutaneous infusion in MPTP-treated common marmosets. Animals received oral administration (0.4 mg/kg, BID) or continuous infusion of ropinirole (0.8 mg/kg/day) via osmotic minipumps for 14 days (Phase I). The treatments were then switched and continued for a further 14 days (Phase II). In Phase I, locomotor activity was similar between treatment groups but reversal of motor disability was more pronounced in animals receiving continuous infusion. Dyskinesia intensity was low in both groups however there was a trend suggestive of less marked dyskinesia in those animals receiving continuous infusion. In Phase II, increased locomotor activity was maintained but animals switched from oral to continuous treatment showing an initial period of enhanced locomotor activity. The reversal of motor disability was maintained in both groups, however, motor disability tended towards greater improvement following continuous infusion. Importantly, dyskinesia remained low in both groups suggesting that constant delivery of ropinirole neither leads to priming nor expression of dyskinesia. These results suggest that a once-daily controlled-release formulation may provide improvements over existing benefits with standard oral ropinirole in Parkinson's disease patients.
authors.affiliation: Neurodegenerative Disease Research Group, School of Health and Biomedical Sciences, King's College London, London, UK.
authors.forename: K A
authors.initials: KA
authors.lastname: Stockwell
authors.forename: D J
authors.initials: DJ
authors.lastname: Virley
authors.forename: M
authors.initials: M
authors.lastname: Perren
authors.forename: M M
authors.initials: MM
authors.lastname: Iravani
authors.forename: M J
authors.initials: MJ
authors.lastname: Jackson
authors.forename: S
authors.initials: S
authors.lastname: Rose
authors.forename: P
authors.initials: P
authors.lastname: Jenner
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001522:Behavior, Animal / Q000187:drug effects; D002144:Callithrix; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D007211:Indoles / Q000008:administration & dosage*; D020267:MPTP Poisoning / Q000150:complications* / Q000188:drug therapy; D009043:Motor Activity / Q000187:drug effects; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology*; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D007211:Indoles; C046649:ropinirole